{"name":"Azienda USL Reggio Emilia - IRCCS","slug":"azienda-usl-reggio-emilia-irccs","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Dexamethasone 0.1% ophthalmic suspension","genericName":"Dexamethasone 0.1% ophthalmic suspension","slug":"dexamethasone-0-1-ophthalmic-suspension","indication":"Inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe","status":"marketed"},{"name":"Diagnostic work up","genericName":"Diagnostic work up","slug":"diagnostic-work-up","indication":"Other","status":"phase_2"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Bromfenac 0.09 % Ophthalmic Solution","genericName":"Bromfenac 0.09 % Ophthalmic Solution","slug":"bromfenac-0-09-ophthalmic-solution","indication":"Postoperative inflammation and pain following ocular surgery","status":"marketed"},{"name":"Bromfenac eye drop","genericName":"Bromfenac eye drop","slug":"bromfenac-eye-drop","indication":"Postoperative inflammation and pain following ocular surgery","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Dexamethasone+Tobramycin eye drop","genericName":"Dexamethasone+Tobramycin eye drop","slug":"dexamethasone-tobramycin-eye-drop","indication":"Bacterial ocular infections with inflammation","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Indomethacin suppository","genericName":"Indomethacin suppository","slug":"indomethacin-suppository","indication":"Rheumatoid arthritis","status":"marketed"}]}],"pipeline":[{"name":"Dexamethasone+Tobramycin eye drop","genericName":"Dexamethasone+Tobramycin eye drop","slug":"dexamethasone-tobramycin-eye-drop","phase":"marketed","mechanism":"Dexamethasone reduces inflammation and immune response while tobramycin kills bacteria, providing combined anti-inflammatory and antibiotic effects in the eye.","indications":["Bacterial ocular infections with inflammation","Post-operative ocular inflammation and infection prophylaxis","Allergic conjunctivitis with secondary bacterial infection"],"catalyst":""},{"name":"Dexamethasone 0.1% ophthalmic suspension","genericName":"Dexamethasone 0.1% ophthalmic suspension","slug":"dexamethasone-0-1-ophthalmic-suspension","phase":"marketed","mechanism":"Dexamethasone is a potent corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors and inhibiting pro-inflammatory mediator production.","indications":["Inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe","Allergic conjunctivitis","Acute inflammatory conditions of the anterior uveal tract","Corneal injury from chemical, radiation, or thermal burns","Post-operative inflammation following ocular surgery"],"catalyst":""},{"name":"Bromfenac 0.09 % Ophthalmic Solution","genericName":"Bromfenac 0.09 % Ophthalmic Solution","slug":"bromfenac-0-09-ophthalmic-solution","phase":"marketed","mechanism":"Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis in the eye.","indications":["Postoperative inflammation and pain following ocular surgery","Reduction of ocular inflammation and pain in patients undergoing cataract surgery"],"catalyst":""},{"name":"Bromfenac eye drop","genericName":"Bromfenac eye drop","slug":"bromfenac-eye-drop","phase":"marketed","mechanism":"Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis in the eye.","indications":["Postoperative inflammation and pain following ocular surgery","Ocular itching associated with allergic conjunctivitis"],"catalyst":""},{"name":"Diagnostic work up","genericName":"Diagnostic work up","slug":"diagnostic-work-up","phase":"phase_2","mechanism":"Diagnostic work up is not a drug but rather a clinical evaluation process to identify and characterize disease.","indications":[],"catalyst":""},{"name":"Indomethacin suppository","genericName":"Indomethacin suppository","slug":"indomethacin-suppository","phase":"marketed","mechanism":"Indomethacin inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.","indications":["Rheumatoid arthritis","Osteoarthritis","Ankylosing spondylitis","Acute pain and inflammation","Patent ductus arteriosus (in neonates)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":6,"phaseCounts":{"marketed":5,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}